- Home
- CABA vs RMNI Comparison
CABA vs RMNI Comparison
Compare CABA & RMNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CABA
- RMNI
- Stock Information
- Founded
- CABA 2017
- RMNI 2005
- Country
- CABA United States
- RMNI United States
- Employees
- CABA N/A
- RMNI N/A
- Industry
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- RMNI Business Services
- Sector
- CABA Health Care
- RMNI Consumer Discretionary
- Exchange
- CABA Nasdaq
- RMNI Nasdaq
- Market Cap
- CABA 210.0M
- RMNI 179.1M
- IPO Year
- CABA 2019
- RMNI N/A
- Fundamental
- Price
- CABA $2.45
- RMNI $2.50
- Analyst Decision
- CABA Strong Buy
- RMNI Buy
- Analyst Count
- CABA 9
- RMNI 2
- Target Price
- CABA $27.22
- RMNI $6.00
- AVG Volume (30 Days)
- CABA 4.7M
- RMNI 502.6K
- Earning Date
- CABA 11-14-2024
- RMNI 10-30-2024
- Dividend Yield
- CABA N/A
- RMNI N/A
- EPS Growth
- CABA N/A
- RMNI N/A
- EPS
- CABA N/A
- RMNI N/A
- Revenue
- CABA N/A
- RMNI $426,650,000.00
- Revenue This Year
- CABA N/A
- RMNI N/A
- Revenue Next Year
- CABA N/A
- RMNI N/A
- P/E Ratio
- CABA N/A
- RMNI N/A
- Revenue Growth
- CABA N/A
- RMNI N/A
- 52 Week Low
- CABA $1.76
- RMNI $1.53
- 52 Week High
- CABA $26.35
- RMNI $3.44
- Technical
- Relative Strength Index (RSI)
- CABA 36.81
- RMNI 63.97
- Support Level
- CABA $2.76
- RMNI $1.95
- Resistance Level
- CABA $2.80
- RMNI $3.00
- Average True Range (ATR)
- CABA 0.42
- RMNI 0.17
- MACD
- CABA -0.05
- RMNI 0.04
- Stochastic Oscillator
- CABA 4.26
- RMNI 53.55
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.
About RMNI Rimini Street Inc. (DE)
Rimini Street Inc is a provider of enterprise software support products and services and a third-party support provider for Oracle and SAP software products based in the United States. The company offers solutions to run, manage, support, customize, configure, connect, protect, monitor, and optimize clients' enterprise applications, databases, and technology software platforms. Some of its products include Oracle E-business suite, Oracle Database, Peoplesoft, SAP business suite, and others. The company derives maximum revenue from United states.